Experience with comprehensive pharmacogenomic multi-gene panel in clinical practice: a retrospective single-center study

AIM: To assess the prevalence of actionable pharmacogenetic interventions in patients who underwent pharmacogenetic testing with a multi-gene panel. METHODS: We retrospectively reviewed single-center electronic health records. A total of 319 patients were enrolled who underwent pharmacogenomic testi...

Descripción completa

Detalles Bibliográficos
Autores principales: Matišić, Vid, Brlek, Petar, Molnar, Vilim, Pavelić, Eduard, Čemerin, Martin, Vrdoljak, Kristijan, Skelin, Andrea, Erceg, Damir, Moravek, Davor, Ivkošić, Ivana Erceg, Primorac, Dragan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Croatian Medical Schools 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9284022/
https://www.ncbi.nlm.nih.gov/pubmed/35722694
http://dx.doi.org/10.3325/cmj.2022.63.257
Descripción
Sumario:AIM: To assess the prevalence of actionable pharmacogenetic interventions in patients who underwent pharmacogenetic testing with a multi-gene panel. METHODS: We retrospectively reviewed single-center electronic health records. A total of 319 patients were enrolled who underwent pharmacogenomic testing with the RightMed test panel using TaqMan quantitative real-time PCR method and copy number variation analysis to determine the SNPs in the 27 target genes. RESULTS: Actionable drug-gene pairs were found in 235 (73.7%) patients. Relevant guidelines on genotype-based prescribing were available for 133 (56.7%) patients at the time of testing. Based on the patients’ genotype, 139 (43.6%) patients were using at least one drug with significant pharmacogenetic interactions. CONCLUSION: Two out of three patients had at least one drug-gene pair in their therapy. Further studies should assess the clinical effectiveness of integrating pharmacogenomic data into patients’ electronic health records.

Ejemplares similares